Top

Published in:

Open Access 01-12-2008 | Research

Detection of somatostatin receptors in human osteosarcoma

Authors: Markos Ioannou, Panayiotis J Papagelopoulos, Ioannis Papanastassiou, Ioanna Iakovidou, Stamatios Kottakis, Nikolaos Demertzis

Published in: World Journal of Surgical Oncology | Issue 1/2008

Abstract

Background

The location of osteosarcoma in the metaphysis as well as the age of the patients during the most rapid tumour growth suggest that factors related to skeletal growth are involved in the pathogenesis of this tumour. In this aspect this study aims to detect somatostatin receptors in human osteosarcomas and correlate this finding with the clinical outcome of the tumour.

Patients and methods

Immunohistochemical staining for the presence of somatostatin receptors as well as overall survival and disease free survival rates were retrospectively studied in twenty-nine osteosarcoma patients.

Results

Four osteosarcomas with several aggressive biologic behaviour expressed somatostatin receptors. In these four young patients the event free rate was 0% and the overall survival rate was 50% at 4, 3 years. In contrast the event free survival rate of the twenty-five patients with negative somatostatin receptor status was 72% with an overall survival rate of 76% at 4,3 years.

Conclusion

The present study demonstrates the existence of somatostatin receptors in human osteosarcoma. Tumours expressing somatostatin receptors seemed to be aggressive with a very low disease free and overall survival rate compared to osteosarcoma with negative receptor status.

Available only for authorised users

Campanacci M: Bone and soft tissue tumors: clinical features, imaging, pathology and treatment. 1999, Padova: Wein: Springer-Verlag, 2CrossRef

Whelan JS: Osteosarcoma. Eur J Cancer. 1997, 33: 1611-1618. 10.1016/S0959-8049(97)00251-7. discussion 1618–1619CrossRefPubMed

Huvos AG: Bone tumors: diagnosis, treatment and prognosis. 1991, Philadelphia; London: W.B. Saunders, 2

Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P: Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer. 2006, 106: 1154-1161. 10.1002/cncr.21724.CrossRefPubMed

Cotterill SJ, Wright CM, Pearce MS, Craft AW: Stature of young people with malignant bone tumors. Pediatr Blood Cancer. 2004, 42: 59-63. 10.1002/pbc.10437.CrossRefPubMed

James RA, Dymock RB: Osteosarcoma associated with acromegaly: a case report. Pathology. 1976, 8: 157-159. 10.3109/00313027609094442.CrossRefPubMed

Pizzo PA, Poplack DG: Principles and practice of pediatric oncology. 2001, Philadelphia; London: Lippincott Williams & Wilkins, 4

Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K: Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer. 1996, 65: 870-874. 10.1002/(SICI)1097-0215(19960315)65:6<870::AID-IJC27>3.0.CO;2-6.CrossRefPubMed

Conzemius MG, Graham JC, Haynes JS, Graham CA: Effects of treatment with growth hormone and somatostatin on efficacy of diammine [1,1-cyclobutane dicarboxylato (2-)-0,0']-(SP-4-2) in athymic rats with osteosarcoma. Am J Vet Res. 2000, 61: 646-650. 10.2460/ajvr.2000.61.646.CrossRefPubMed

10.

Khanna C, Prehn J, Hayden D, Cassaday RD, Caylor J, Jacob S, Bose SM, Hong SH, Hewitt SM, Helman LJ: A randomized controlled trial of octreotide pamoate long-acting release and carboplatin versus carboplatin alone in dogs with naturally occurring osteosarcoma: evaluation of insulin-like growth factor suppression and chemotherapy. Clin Cancer Res. 2002, 8: 2406-2412.PubMed

11.

Koper JW, Markstein R, Kohler C, Kwekkeboom DJ, Avezaat CJ, Lamberts SW, Reubi JC: Somatostatin inhibits the activity of adenylate cyclase in cultured human meningioma cells and stimulates their growth. J Clin Endocrinol Metab. 1992, 74: 543-547. 10.1210/jc.74.3.543.PubMed

12.

Ganz MB, Pachter JA, Barber DL: Multiple receptors coupled to adenylate cyclase regulate Na-H exchange independent of cAMP. J Biol Chem. 1990, 265: 8989-8992.PubMed

13.

Reubi JC, Laissue J, Krenning E, Lamberts SW: Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992, 43: 27-35. 10.1016/0960-0760(92)90184-K.CrossRefPubMed

14.

Daw NC, Billups CA, Rodriguez-Galindo C, McCarville MB, Rao BN, Cain AM, Jenkins JJ, Neel MD, Meyer WH: Metastatic osteosarcoma. Cancer. 2006, 106: 403-412. 10.1002/cncr.21626.CrossRefPubMed

15.

Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, Applewhite A, Vlamis V, Rosen G: Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol. 1992, 10: 5-15.PubMed

16.

Bacci G, Ferrari S, Mercuri M, Longhi A, Fabbri N, Galletti S, Forni C, Balladelli A, Serra M, Picci P: Neoadjuvant chemotherapy for osteosarcoma of the extremities in patients aged 41–60 years: outcome in 34 cases treated with adriamycin, cisplatinum and ifosfamide between 1984 and 1999. Acta Orthop. 2007, 78: 377-384. 10.1080/17453670710013960.CrossRefPubMed

17.

Alumets J, Sundler F, Hakanson R: Distribution, ontogeny and ultrastructure of somatostatin immunoreactive cells in the pancreas and gut. Cell Tissue Res. 1977, 185: 465-479. 10.1007/BF00220651.CrossRefPubMed

18.

Erlandsen SL, Hegre OD, Parsons JA, McEvoy RC, Elde RP: Pancreatic islet cell hormones distribution of cell types in the islet and evidence for the presence of somatostatin and gastrin within the D cell. J Histochem Cytochem. 1976, 24: 883-897.CrossRefPubMed

19.

Parsons JA, Erlandsen SL, Hegre OD, McEvoy RC, Elde RP: Central and peripheral localization of somatostatin. Immunoenzyme immunocytochemical studies. J Histochem Cytochem. 1976, 24: 872-882.CrossRefPubMed

20.

Srkalovic G, Cai RZ, Schally AV: Evaluation of receptors for somatostatin in various tumors using different analogs. J Clin Endocrinol Metab. 1990, 70: 661-669.CrossRefPubMed

21.

Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K, O'Byrne K, Cai RZ: Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude mice. Br J Cancer. 1994, 70: 886-892.PubMedCentralCrossRefPubMed

22.

Enneking WF: A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986, 9-24.

23.

Bacci G, Ferrari S, Bertoni F, Ruggieri P, Picci P, Longhi A, Casadei R, Fabbri N, Forni C, Versari M, Campanacci M: Long-term outcome for patients with nonmetastatic osteosarcoma of the extremity treated at the istituto ortopedico rizzoli according to the istituto ortopedico rizzoli/osteosarcoma-2 protocol: an updated report. J Clin Oncol. 2000, 18: 4016-4027.PubMed

24.

Fuchs N, Bielack SS, Epler D, Bieling P, Delling G, Korholz D, Graf N, Heise U, Jurgens H, Kotz R: Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group's protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998, 9: 893-899. 10.1023/A:1008391103132.CrossRefPubMed

25.

Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT, Miser JS: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol. 1997, 15: 76-84.PubMed

26.

Finkel MP, Reilly CA, Biskis BO: Pathogenesis of radiation and virus-induced bone tumors. Recent Results Cancer Res. 1976, 92-103.

27.

Swaney JJ: Familial osteogenic sarcoma. Clin Orthop Relat Res. 1973, 64-68. 10.1097/00003086-197311000-00010.

28.

Guyton AC, Hall JE: Textbook of medical physiology. 2006, Edinburgh: Elsevier Saunders; Oxford: Elsevier Science [distributor], 11

29.

Mansky PJ, Liewehr DJ, Steinberg SM, Chrousos GP, Avila NA, Long L, Bernstein D, Mackall CL, Hawkins DS, Helman LJ: Treatment of metastatic osteosarcoma with the somatostatin analog OncoLar: significant reduction of insulin-like growth factor-1 serum levels. J Pediatr Hematol Oncol. 2002, 24: 440-446. 10.1097/00043426-200208000-00007.CrossRefPubMed

30.

Ferrari S, Dondi M, Fanti S, Zoboli S, Giacomini S, Mercuri M, Bacci G: Somatostatin receptor (SSTR) scintigraphy in patients with osteosarcoma. Cancer Biother Radiopharm. 2003, 18: 847-851. 10.1089/108497803770418391.CrossRefPubMed

Title: Detection of somatostatin receptors in human osteosarcoma
Authors: Markos Ioannou
Panayiotis J Papagelopoulos
Ioannis Papanastassiou
Ioanna Iakovidou
Stamatios Kottakis
Nikolaos Demertzis
Publication date: 01-12-2008
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2008
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/1477-7819-6-99

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Detection of somatostatin receptors in human osteosarcoma

Abstract

Background

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2008

Upper abdominal body shape is the risk factor for postoperative pancreatic fistula after splenectomy for advanced gastric cancer: A retrospective study

Adrenocortical oncocytic carcinoma with recurrent metastases: a case report and review of the literature

A rare case of isolated wound implantation of colorectal adenocarcinoma complicating an incisional hernia: case report and review of the literature

Neoangiogenesis in early cervical cancer: Correlation between color Doppler findings and risk factors. A prospective observational study

Segmental resection of the duodenum for gastrointestinal stromal tumor (GIST)

Resection of giant ethmoid osteoma with orbital and skull base extension followed by duraplasty